Ali Yaman
Overview
Explore the profile of Ali Yaman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akgun D, Avci E, Yaman A, Safak O, Kisacik H, Argan O, et al.
Anatol J Cardiol
. 2024 Jan;
PMID: 38168010
Background: Endocan is an indicator of many pathologies accompanied by inflammation, endothelial cell activation, and dysfunction. In this study, we examined the relationship between degenerative aortic sclerosis, which progresses in...
2.
Gacemer H, Gurpinar Tosun B, Helvacioglu D, Yaman A, Yavas Abali Z, Haliloglu B, et al.
Eur J Pediatr
. 2023 Dec;
183(3):1325-1332.
PMID: 38133811
Although hypothalamo-pituitary-gonadal axis is active during mini-puberty, its relationship with somatic growth and the role on the development of external genitalia has not been fully elucidated. We aimed to evaluate...
3.
Yazan C, Yaman A, Haklar G, Sirikci O, Deyneli O
J Diabetes Metab Disord
. 2022 Jun;
21(1):689-695.
PMID: 35673502
Aim: Vitamin D deficiency is known to be associated with metabolic bone diseases. The aim of this study is to evaluate vitamin D and calculated free and bioactive vitamin D...
4.
Yildiz M, Isik E, Yavas Abali Z, Keskin M, Ozbek M, Bas F, et al.
J Clin Endocrinol Metab
. 2021 Apr;
106(9):e3714-e3724.
PMID: 33830237
Background: Given the rarity of 11β-hydroxylase deficiency (11βOHD), there is a paucity of data about the differences in clinical and biochemical characteristics of classic (C-11βOHD) and nonclassic 11βOHD (NC-11βOHD). Objective:...
5.
Yaman A, Gerin F, Baykan O, Sirikci O, Haklar G
J Appl Lab Med
. 2020 Dec;
1(6):767-770.
PMID: 33379833
No abstract available.
6.
Guven S, Gokce I, Cicek N, Yaman A, Vatansever P, Alpay H
J Pediatr Endocrinol Metab
. 2020 Oct;
33(11):1383-1390.
PMID: 33068383
Background Sclerostin and osteoprotegerin (OPG) are new markers of chronic kidney disease (CKD) mediated mineral bone disease (CKD-MBD) which were extensively evaluated in adult population. We aimed to evaluate the...
7.
Gurbuz A, Ozturk S, Efe S, Yilmaz M, Yanik R, Yaman A, et al.
Med Princ Pract
. 2019 Sep;
28(6):573-580.
PMID: 31480068
Objective: Heparanase (HPA), mammalian endo-β-D-glu-cu-ronidase, separates heparan sulfate chains of proteoglycans and changes the structure of the extracellular matrix. We investigated whether serum levels of HPA differ in patients with...
8.
Gurbuz A, Ozturk S, Efe S, Yilmaz M, Yanik R, Yaman A, et al.
Biomarkers
. 2019 Jun;
24(6):600-606.
PMID: 31215255
Heparanase (HPA) is an endo-β-D-glucuronidase capable of degrading heparin sulphate (HS) and heparin side chains. HPA plays a role in tumour growth, angiogenesis, cell invasion and in activation of the...
9.
Baykan O, Akgul M, Uren N, Yaman A, Tinay I, Ergul E, et al.
Clin Lab
. 2019 Apr;
65(4).
PMID: 30969078
Background: Bladder cancer is an important health problem which ranks 4th among most frequently seen cancer types in men. In our study we aimed to investigate the correlations among urothelial...
10.
Bayam E, Kalcik M, Gurbuz A, Yesin M, Guner A, Gunduz S, et al.
Thromb Res
. 2018 Oct;
171:103-110.
PMID: 30273810
Introduction: Procoagulant activity of heparanase has been recently described in several arterial and venous thrombotic disorders. In this study, we aimed to investigate the role of heparanase with regard to...